Conversely, candidate cancer therapeutics targeting the PI3K pathway bring hope for much needed targeted therapies for PROS, as recently demonstrated in an uncontrolled case series treated with the p110α-specific inhibitor Alpelisib (BYL719) [4]. This evidence concerns the gene PIK3CB and cancer.